Marc Righini
Marc Righini is an expert in Hematology at University Hospital of Geneva (Switzerland). As of October 2026, ScienceLeadR ranks Marc Righini in the top 1% of experts worldwide for Pulmonary Embolism and Embolism and Thrombosis. Marc Righini has authored 490 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 4 of them ongoing. SLR score: 1,845 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Cardiology - Public Health - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
- Top Embolism and Thrombosis key opinion leaders — ranked #18
Organizations
Career arc: 2000 - 2026
Number : 490
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 37
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Early Exercise Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism NCT07143539 — depression, exercise, physical therapists, quality of life, exercise tolerance, thromboembolism, rehabilitation centers, embolism, safety, exercise therapy, venous thrombosis, rehabilitation, signs and symptoms, pulmonary embolism, anxiety disorders, diagnosis, therapeutics, venous thromboembolism, resistance training, thrombosis, dyspnea, outpatients, education, veins, functional status | N/A | Recruiting | 2025 |
| The API CALF Study Apixaban to Treat Calf Vein Thrombosis NCT04981327 — anticoagulants, venous thrombosis, tablets, therapeutics, thrombosis, veins, direct-acting oral anticoagulants, apixaban | Phase 3 | Not yet recruiting | 2022 |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk NCT04774159 — mortality, stroke, myocardial infarction, colchicine, pharmaceutical preparations, tablets, arteries, atherosclerosis, peripheral arterial disease, therapeutics, ischemia | Phase 3 | Recruiting | 2021 |
| Pulmonary Embolism International THrOmbolysis Study 3 NCT04430569 — embolism, plasminogen, plasminogen activators, tissue plasminogen activator, pulmonary embolism, therapeutics, tissues, infusions, intravenous | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map